1. All Articles

    1-24 of 3098 1 2 3 4 ... 127 128 129 »
    1. LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      Clin Cancer Res. 2018 Jun 20;:

      Authors: Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, De Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C

      Read Full Article
      Mentions: MYCN LDH
    2. Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Int J Cancer. 2018 Jun 21;:

      Authors: Norsker FN, Rechnitzer C, Cederkvist L, Tryggvadottir L, Madanat-Harjuoja LM, Øra I, Thorarinsdottir HK, Vettenranta K, Bautz A, Schrøder H, Hasle H, Winther JF

      Read Full Article
    3. Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Pediatr Blood Cancer. 2018 Jun 19;:e27248

      Authors: Flynn N, LeFebvre A, Messahel B, Hogg SL

      Abstract Measurement of the urine catecholamine metabolites homovanillic acid (HVA) and vanillylmandelic acid (VMA) are the standard method for detecting disease recurrence in neuroblastoma.

      Read Full Article
    4. Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Pediatr Transplant. 2018 Jun 19;:e13240

      Authors: Liu APY, Lee PPW, Kwok JSY, Leung RYY, Chiang AKS, Ha SY, Cheuk DKL, Chan GCF

      Abstract Relapsed/refractory NB carries a bleak outcome, warranting novel treatment options. HaploHSCT induces a graft-versus-NB effect via natural killer cell alloreactivity.

      Read Full Article
    5. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Clin Nucl Med. 2018 Jun 19;:

      Authors: Willegaignon J, Crema KP, Oliveira NC, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA

      Read Full Article
    6. New method to preserve boy cancer patient fertility being developed

      New method to preserve boy cancer patient fertility being developed

      Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center researchers in Beer-Sheva, Israel are developing a cell culture system that for the first time can change testicular stem cells into sperm-like cells that may enable future fertility for boys with prepubertal cancer.

      Read Full Article
      Mentions: Genetics
    7. Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      J Adv Pract Oncol. 2017 Jan-Feb;8(1):44-55

      Authors: Armideo E, Callahan C, Madonia L

      Abstract Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials.

      Read Full Article
    8. Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Oncotarget. 2018 May 25;9(40):26157-26170

      Authors: Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Gironella M, Ritort F, Cañete A, Bueno G, Navarro S, Noguera R

      Abstract Neuroblastoma is the most common extra-cranial solid pediatric cancer and causes approximately 15% of all childhood deaths from cancer.

      Read Full Article
    9. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

      Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

      Neuroblastoma is a pediatric cancer of the sympathetic nervous system where MYCN amplification is a key indicator of poor prognosis. However, mechanisms by which MYCN promotes neuroblastoma tumorigenesis are not fully understood. In this study, we analyzed global miRNA and mRNA expression profiles of tissues at different stages of tumorigenesis from TH-MYCN transgenic mice, a model of MYCN-driven neuroblastoma.

      Read Full Article
      Mentions: Imaging MYCN Genetics
    10. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      J Natl Compr Canc Netw. 2018 Jun;16(6):683-691

      Authors: Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W

      Abstract Metachronous neoplasms have rarely been reported in patients with neuroblastoma.

      Read Full Article
      Mentions: ALK
    11. CureWorks Collaborative Launches to Accelerate Development of Immunotherapy Treatments for Childhood Cancers, Increase Access to Clinical Trials

      Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. CureWorks focuses on expanding immunotherapy trials and patient access around the world, as well as sharing data and collective expertise to advance novel cell therapies.

      Read Full Article
      Mentions: Immunotherapy
    12. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Cancer. 2018 Jun 11;:

      Authors: Zheng DJ, Krull KR, Chen Y, Diller L, Yasui Y, Leisenring W, Brouwers P, Howell R, Lai JS, Balsamo L, Oeffinger KC, Robison LL, Armstrong GT, Kadan-Lottick NS

      Read Full Article
    13. Children with neuroblastoma have an elevated risk of long-term psychological difficulties

      A new study reveals that paediatric neuroblastoma patients are at elevated risk for long-term psychological impairment.

      In addition, those who experience such impairment as they get older tend to require special education services and to not go on to...

      Read Full Article
      Mentions: Treatment
    14. President Signs STAR Act for Kids' Cancers.

      President Signs STAR Act for Kids' Cancers.

      Cancer Discov. 2018 Jun 07;:

      Authors:

      Abstract On June 5, President Donald Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research Act, which aims to support pediatric cancer research by expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

      PMID: 29880581 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Treatment
    15. Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Biol Direct. 2018 Jun 07;13(1):12

      Authors: Tranchevent LC, Nazarov PV, Kaoma T, Schmartz GP, Muller A, Kim SY, Rajapakse JC, Azuaje F

      Abstract BACKGROUND: One of the main current challenges in computational biology is to make sense of the huge amounts of multidimensional experimental data that are being produced.

      Read Full Article
    16. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Oncogene. 2018 Jun 07;:

      Authors: Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, Califano A, Yamashiro DJ

      Read Full Article
      Mentions: MYCN
    17. Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis.

      Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis.

      Cancer Manag Res. 2018;10:1359-1364

      Authors: Yin Z, Wang Y, Wu Y, Zhang X, Wang F, Wang P, Tao Z, Yuan Z

      Abstract Objective: The objective of the study was to describe the age distribution and to evaluate the role of prognostic value of age on survival in patients diagnosed with olfactory neuroblastoma (ONB). A population-based retrospective analysis was conducted.

      Read Full Article
    18. Comparison of long-term prognosis of laparoscopic and open adrenalectomy for local adrenal neuroblastoma in children.

      Comparison of long-term prognosis of laparoscopic and open adrenalectomy for local adrenal neuroblastoma in children.

      Pediatr Surg Int. 2018 Jun 07;:

      Authors: Yao W, Dong K, Li K, Zheng S, Xiao X

      Abstract OBJECTIVE: To investigate and compare long-term outcomes in children undergoing laparoscopic or open adrenalectomy for local adrenal neuroblastoma.

      Read Full Article
    1-24 of 3098 1 2 3 4 ... 127 128 129 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. INBRACED

    See all INBRACED articles
  4. Organizations in the News

    1. (88 articles) COG
    2. (27 articles) NANT
    3. (23 articles) SIOPEN
    4. (23 articles) SIOP
    5. (18 articles) MSKCC
    6. (16 articles) INRG
    7. (16 articles) GPOH
    8. (11 articles) NMTRC
  5. Locations in the News

    1. (9 articles) Other Countries
  6. Researches in the News

    1. (295 articles) MYCN
    2. (224 articles) Immunotherapy
    3. (143 articles) Antibody
    4. (127 articles) ALK
    5. (93 articles) Imaging
    6. (76 articles) T-Cells
    7. (65 articles) Bone Marrow
    8. (52 articles) Metastasis
    9. (49 articles) ASCO
    10. (34 articles) Genetics
  7. General Informations in the News

    1. (458 articles) Treatment
    2. (24 articles) Staging
    3. (6 articles) Hearing Loss
  8. Treatments in the News

    1. (108 articles) Surgery
    2. (105 articles) Chemotherapy
    3. (100 articles) Refractory
    4. (89 articles) MIBG
    5. (73 articles) Relapse
    6. (69 articles) Stem Cell Transplant
    7. (65 articles) Radiotherapy
    8. (24 articles) Side Effects
    9. (20 articles) Diagnostics
    10. (9 articles) Targetted Therapy